Press Releases Johnson & Johnson Bulgaria S.E.

Equities

JNJ

US4781601046

Real-time Estimate Tradegate Other stock markets 15:00:47 28/05/2024 BST			5-day change	1st Jan Change
134.5 ^EUR	-4.37%		+1.43%	-11.49%

03:59pm	Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	MT
03:15pm	Johnson & Johnson to Acquire Experimental Eczema Drug for $1.25 Billion	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Numab Therapeutics Announces Johnson & Johnson to Acquire its Wholly-Owned Subsidiary Yellow Jersey Therapeutics Including Rights to NM26, a Bi-Specific Antibody for the Treatment of Atopic Dermatitis	12:35pm	AQ
Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis	12:32pm	BU
Johnson & Johnson: Meet a nurse who leads clinical trials to find innovative cancer therapies	05-24	AQ
Johnson & Johnson : advances leadership in oncology innovation with more than 75 clinical study and real-world presentations at ASCO and EHA	05-24	PU
Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation	05-22	BU
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences	05-22	AQ
TREMFYA (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission	05-21	AQ
Novel biologic could offer ulcerative colitis symptomatic remission	05-21	AQ
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation	05-21	AQ
Johnson & Johnson : to Participate in the 2024 RBC Capital Markets Global Healthcare Conference Transcript	05-17	PU
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment	05-16	BU
Johnson & Johnson : to Participate in the BofA Securities Health Care Conference Transcript	05-15	PU
Johnson & Johnson : to Participate in the 2024 RBC Capital Markets Global Healthcare Conference Press Release	05-15	PU
Johnson & Johnson : to Participate in the BofA Securities Health Care Conference Press Release	05-15	PU
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	05-08	BU
Intravesical drug delivery system exhibits bladder cancer benefit	05-07	AQ
Johnson & Johnson - Phase 2 data for ERLEADA plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate	05-06	AQ
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024	05-06	AQ
Johnson & Johnson - TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer	05-06	AQ
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA (guselkumab) for treatment of patients with ulcerative colitis and Crohn's disease	05-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 05:30 pm